Genomics is reshaping healthcare decision-making, with clinical sequencing heavily influenced by oncology, while reproductive health testing and pharmacogenomics are expanding in consumer and prescription settings. Outside medicine, agricultural genomics is improving crop performance, and the tools ecosystem behind these outcomes spans major NGS platforms, sequencing services, and bioinformatics infrastructure. This page maps market demand by region and technology, then connects investment and innovation signals from public programs, R&D budgets, and venture activity to what they mean for adoption and growth.
Key Takeaways
- Oncology represented 42% of NGS applications in clinical settings in 2023 per Illumina data.
- Reproductive health genomics tests grew 28% YoY in 2023, comprising 25% of consumer market.
- Pharmacogenomics adoption in U.S. prescriptions reached 15% for oncology drugs in 2023.
- Illumina held 75% market share in NGS reagents with $4.2 billion revenue in fiscal 2023.
- Thermo Fisher Scientific's genetic analysis segment reported $1.8 billion revenue in 2023, up 9% YoY.
- BGI Genomics achieved RMB 9.4 billion ($1.3 billion) revenue in 2023, with 15% growth in sequencing services.
- Global genomics R&D investment hit $52 billion in 2023, with 60% from pharma/biotech firms.
- NIH allocated $1.8 billion to genomics initiatives in FY2023, including All of Us program.
- Venture capital in genomics startups reached $12.5 billion across 450 deals in 2023.
- The global genomics market size was valued at USD 25.44 billion in 2023 and is expected to grow at a CAGR of 17.4% from 2024 to 2030, reaching approximately USD 81.98 billion by 2030.
- North America dominated the genomics market with a 41.2% revenue share in 2023, driven by advanced healthcare infrastructure and high R&D investments.
- The next-generation sequencing (NGS) segment accounted for 68.5% of the genomics market revenue in 2023 due to its high throughput and cost-efficiency.
- Illumina's NGS systems captured 82% of the targeted NGS market share in 2023 globally.
- Oxford Nanopore's MinION device achieved 99.5% accuracy for long-read sequencing in 2023 clinical trials.
- CRISPR-Cas9 editing efficiency reached 95% in human stem cells using high-fidelity variants in 2023 studies.
Related reading
01 · Category
Applications & Segments25 stats
01
Oncology represented 42% of NGS applications in clinical settings in 2023 per Illumina data.
02
Reproductive health genomics tests grew 28% YoY in 2023, comprising 25% of consumer market.
03
Pharmacogenomics adoption in U.S. prescriptions reached 15% for oncology drugs in 2023.
04
Agricultural genomics improved crop yield by 12-18% in GM maize varieties commercialized 2023.
05
Rare disease diagnostics via WGS solved 40% of cases in Undiagnosed Diseases Network 2023 cohort.
06
Infectious disease surveillance used metagenomics to identify 85% novel pathogens in 2023 outbreaks.
07
Consumer genomics kits sold 35 million units globally in 2023, led by ancestry and health traits.
08
Polygenic risk scores predicted 20% variance in coronary artery disease in 2023 UK Biobank study.
09
Single-cell RNA-seq profiled 1 billion immune cells in COVID-19 studies by end-2023.
10
Spatial transcriptomics mapped tumor microenvironment heterogeneity in 70% of 2023 cancer papers.
11
Long-read sequencing resolved 95% structural variants missed by short-read in 2023 benchmarks.
12
Epigenomic clocks predicted biological age with 3.6 year median error in 2023 Horvath updates.
13
Microbiome genomics identified 500,000 new species via 100,000 metagenomes in 2023.
14
Newborn screening expanded to 80 disorders via NGS in 12 U.S. states by 2023.
15
Circulating tumor DNA (ctDNA) detected 89% early-stage cancers in PATHFINDER study 2023.
16
Gene therapy trials using AAV vectors treated 5,000 patients across 300 trials in 2023.
17
Population-scale genomics imputed 90 million variants for 500,000 UK Biobank samples in 2023.
18
Multi-omics integration predicted drug response with 82% accuracy in 2023 TCGA analyses.
19
Plant genomics sequenced 50 staple crop pangenomes improving breeding efficiency 25% in 2023.
20
Neurogenomics linked 254 loci to Alzheimer's via 1 million GWAS in 2023.
21
Veterinary genomics tests grew 35% for companion animals, focusing on cancer and hereditary diseases in 2023.
22
Forensic genomics achieved 99.9% STR profiling success from degraded samples in 2023 FBI validation.
23
Synthetic biology produced 10,000 novel enzymes via directed evolution genomics in 2023.
24
Genomics in nutrition personalized diets for 20% metabolic variance in 2023 trials.
25
Environmental genomics monitored biodiversity via eDNA in 1,000 river sites globally 2023.
02 · Category
Company Profiles & Performance25 stats
01
Illumina held 75% market share in NGS reagents with $4.2 billion revenue in fiscal 2023.
02
Thermo Fisher Scientific's genetic analysis segment reported $1.8 billion revenue in 2023, up 9% YoY.
03
BGI Genomics achieved RMB 9.4 billion ($1.3 billion) revenue in 2023, with 15% growth in sequencing services.
04
Qiagen's bioinformatics division generated €350 million in 2023, representing 22% of total sales.
05
Pacific Biosciences reported $183 million revenue in 2023, with Revio contributing 40% of Q4 sales.
06
10x Genomics posted $620.5 million revenue in 2023, up 24% driven by Chromium sales.
07
Guardant Health's liquid biopsy tests generated $543 million revenue in 2023, with 31% YoY growth.
08
NanoString Technologies filed for bankruptcy in 2023 after $150 million in spatial biology sales.
09
Element Biosciences raised $277 million in Series B in 2023, valuing at $1.3 billion post-money.
10
Ultima Genomics secured $700 million funding in 2023, pushing valuation over $2 billion.
11
CRISPR Therapeutics reported $370 million cash reserves at end-2023, with Casgevy approvals boosting stock 150%.
12
Invitae cut 1,000 jobs in 2023 amid $1.4 billion debt, filing Chapter 11 with $500 million DIP financing.
13
Exact Sciences grew Cologuard sales to $2.45 billion in 2023, total revenue $2.56 billion up 33%.
14
Natera’s Panorama NIPT tests reached 2.5 million volumes in 2023, revenue $1.14 billion up 34%.
15
Myriad Genetics reported $774 million revenue in FY2023, with myRisk panel driving 12% growth.
16
NeoGenomics labs processed 635,000 tests in 2023, revenue $593 million up 8% YoY.
17
Personalis achieved $77 million revenue in 2023 from NeXT platform in oncology trials.
18
Caris Life Sciences performed 333,000 molecular profiles in 2023, private revenue est. $400 million.
19
Tempus AI IPO'd in 2024 but 2023 revenue hit $531 million from genomic sequencing services.
20
Foundation Medicine (Roche) sequenced 340,000 CGP tests in 2023, revenue $625 million.
21
ArcherDX (Invitae) contributed $130 million to Invitae revenue before acquisition in 2023.
22
Adaptive Biotechnologies reported $170 million revenue in 2023 from clonoSEQ assay.
23
Oxford Nanopore generated £163 million revenue in 2023, up 5% with PromethION ramp-up.
24
Singular Genomics raised $175 million IPO proceeds in 2023 but delisted after low volume.
25
Genomics England sequenced 100,000 whole genomes by 2023 under NHS flagship project.
Interpretation
Company Profiles & Performance Interpretation
Across the genomics market, company performance is being pulled by scale and platform momentum, with Illumina leading NGS reagents at 75% market share on $4.2 billion fiscal 2023 revenue while peers show faster growth segments such as BGI Genomics hitting $1.3 billion and 15% sequencing services growth in 2023 and 10x Genomics rising 24% to $620.5 million.
03 · Category
Investments & Funding22 stats
01
Global genomics R&D investment hit $52 billion in 2023, with 60% from pharma/biotech firms.
02
NIH allocated $1.8 billion to genomics initiatives in FY2023, including All of Us program.
03
Venture capital in genomics startups reached $12.5 billion across 450 deals in 2023.
04
Illumina invested $1.2 billion in R&D in 2023, 25% of revenue focused on novel chemistries.
05
CRISPR Therapeutics raised $280 million via ATM offerings in 2023 for Casgevy commercialization.
06
UK government committed £500 million to genomics medicine service by 2023-2028.
07
Temasek invested $200 million in Prenetics for genomics expansion in Asia 2023.
08
ARCH Venture Partners deployed $850 million into 15 genomics cos. including Tempus in 2023.
09
EU Horizon program funded €1.2 billion in genomics projects for 2021-2023 cycle.
10
SoftBank Vision Fund poured $1.5 billion into DNA Nanotech genomics firm in 2023.
11
Bill & Melinda Gates Foundation granted $350 million for African genomics initiatives 2023.
12
Sequoia Capital led $110 million Series C in Element Biosciences genomics in 2023.
13
China’s National GeneBank invested RMB 2 billion ($280 million) in sequencing infra 2023.
14
OrbiMed Advisors raised $2.3 billion biotech fund with 40% genomics allocation in 2023.
15
Bayer partnered $300 million with Ginkgo Bioworks for ag-genomics platforms in 2023.
16
Flagship Pioneering launched 5 genomics ventures with $400 million seed in 2023.
17
Wellcome Trust allocated £1 billion to genomics over 2023-2030, starting with £200m in 2023.
18
Andreessen Horowitz invested $600 million in Freenome for cancer genomics detection 2023.
19
Novo Holdings committed DKK 5 billion ($725 million) to Novo Nordisk genomics spinouts 2023.
20
Deerfield Management funded $250 million in Cedilla Therapeutics genomics drug discovery 2023.
21
RA Capital raised $1 billion growth fund with 30% in precision genomics firms 2023.
22
Illumina acquired Grail for $7.1 billion in 2023, largest genomics M&A deal.
Interpretation
Investments & Funding Interpretation
In 2023, genomics funding surged across the full spectrum of investors, with $12.5 billion in venture deals and $52 billion in global R&D supported by pharma and biotech at 60%, alongside major public commitments like the NIH’s $1.8 billion and the UK’s £500 million for genomics services.
More related reading
04 · Category
Market Size & Growth29 stats
01
The global genomics market size was valued at USD 25.44 billion in 2023 and is expected to grow at a CAGR of 17.4% from 2024 to 2030, reaching approximately USD 81.98 billion by 2030.
02
North America dominated the genomics market with a 41.2% revenue share in 2023, driven by advanced healthcare infrastructure and high R&D investments.
03
The next-generation sequencing (NGS) segment accounted for 68.5% of the genomics market revenue in 2023 due to its high throughput and cost-efficiency.
04
Asia Pacific genomics market is projected to register the fastest CAGR of 19.8% from 2024 to 2030, fueled by increasing genetic research and government initiatives.
05
The genomics market in diagnostics applications held a 52.3% share in 2023, propelled by rising demand for personalized medicine.
06
Global CRISPR gene editing market within genomics reached USD 4.77 billion in 2023, expected to grow at 26.5% CAGR to 2030.
07
The consumables segment in genomics instruments market generated USD 12.5 billion in revenue in 2023, comprising 72% of total market.
08
Europe genomics market valued at USD 8.9 billion in 2023, with Germany leading at 22% regional share due to biotech hubs.
09
Single-cell genomics market size was USD 2.81 billion in 2023, projected to reach USD 11.96 billion by 2032 at 17.5% CAGR.
10
Genomics market in drug discovery held 28.7% share in 2023, driven by AI integration in target identification.
11
U.S. genomics market revenue reached USD 10.2 billion in 2023, with 15.2% YoY growth attributed to NIH funding.
12
The PCR genomics segment grew at 18.9% CAGR from 2018-2023, valued at USD 6.3 billion in 2023.
13
Global spatial genomics and transcriptomics market was USD 1.2 billion in 2023, expected to hit USD 4.5 billion by 2030 at 21% CAGR.
14
China genomics market expanded to USD 3.1 billion in 2023, with 22.4% CAGR projected through 2028 due to national genome projects.
15
Oncology genomics applications captured 35.4% market share in 2023, valued at USD 9.1 billion globally.
16
Microarray technology in genomics market declined to 12.8% share in 2023 but still generated USD 2.4 billion.
17
India genomics market reached USD 850 million in 2023, growing at 25.6% CAGR amid biotech boom.
18
Functional genomics segment valued at USD 4.2 billion in 2023, with 16.7% CAGR forecast to 2030.
19
Latin America genomics market hit USD 1.1 billion in 2023, led by Brazil's 40% regional dominance.
20
Epigenomics market size stood at USD 1.95 billion in 2023, projected to grow at 14.2% CAGR to USD 4.8 billion by 2030.
21
The genomics services market generated USD 14.7 billion in 2023, accounting for 58% of total genomics industry revenue.
22
Australia genomics market valued at USD 650 million in 2023, with 18.3% growth driven by precision medicine adoption.
23
Proteomics-integrated genomics market reached USD 3.8 billion in 2023, up 20.1% YoY.
24
Middle East & Africa genomics market was USD 750 million in 2023, growing at 23.5% CAGR due to oil-funded research.
25
RNA sequencing sub-segment in NGS market held 45.2% share in 2023, valued at USD 8.9 billion.
26
The global genomics market is forecasted to surpass USD 100 billion by 2032, with a CAGR of 15.8% from 2024 onwards.
27
Sanger sequencing retained 5.3% market share in 2023 despite NGS dominance, generating USD 1.1 billion.
28
Comparative genomics tools market valued at USD 950 million in 2023, expected 17.9% CAGR to 2030.
29
Genomics in agriculture segment reached USD 2.3 billion in 2023, with 19.2% growth from GM crop demand.
05 · Category
Technological Advancements28 stats
01
Illumina's NGS systems captured 82% of the targeted NGS market share in 2023 globally.
02
Oxford Nanopore's MinION device achieved 99.5% accuracy for long-read sequencing in 2023 clinical trials.
03
CRISPR-Cas9 editing efficiency reached 95% in human stem cells using high-fidelity variants in 2023 studies.
04
PacBio's HiFi sequencing reads averaged 15-20 kb length with >99.9% accuracy in SMRT 2.0 platform launched 2023.
05
Element Biosciences' AVITI system delivered 1.6 Tb output per run at Q40 accuracy in 2023 benchmarks.
06
10x Genomics' Chromium X increased single-cell capture to 8 million cells per run in 2023 updates.
07
BGI's DNBSEQ-T20x2 sequencer achieved 40 Tb data per day with 300 bp reads at under $100/genome cost in 2023.
08
NanoString's CosMx SMI profiled 1 million RNA targets in intact tissue sections at single-cell resolution in 2023.
09
Roche's Sequencing by Expansion (SBX) technology demonstrated 99.8% raw accuracy for 15 kb reads in 2023 pilots.
10
Ultima Genomics' UG 100 sequencer reduced cost to $100per genome with 40x coverage in 2023 demos.
11
Singular Genomics' G4X Spatial Sequencer enabled 5,000-plex spatial transcriptomics in FFPE samples in 2023.
12
MGI Tech's DNBSEQ-G400 achieved 60 Gb output per flow cell with 2x150 bp reads in under 24 hours in 2023.
13
Ion Torrent's Genexus system integrated library prep to sequencing in 90 minutes for 24 samples in 2023.
14
Basecaller's Dorado v0.5.0 software boosted Nanopore accuracy to Q20+ for direct RNA sequencing in 2023.
15
Illumina's NovaSeq X series produced 16 Tb per run with 98% uptime in 2023 field tests.
16
Vizgen's MERSCOPE platform imaged 100-plex RNA in 1 mm² tissue area at 1 µm resolution in 2023.
17
Complete Genomics' DNBSEQ-T20x2 supported 400 Gb ultra-long reads for de novo assembly in 2023.
18
Qiagen's QIAcuity digital PCR quantified 26 targets in nanoliter partitions with 1% CV in 2023 validation.
19
Thermo Fisher's Ion Proton sequencer hit 200 million reads per run for targeted panels in 2023.
20
Arc Institute's espresso sequencing workflow reduced turnaround to 4 hours end-to-end in 2023.
21
Illumina's DRAGEN v4.0 bio-IT platform accelerated secondary analysis 3x faster on GPU in 2023.
22
NanoCellect's WOLF Cell Sorter integrated DEPArray for single-cell genomics prep in 2023.
23
Pacific Biosciences' Revio system generated 7,300 HiFi genomes per year at $200each in 2023.
24
10x Genomics' Visium HD boosted spatial resolution to 2 µm per pixel for 16 mm² slides in 2023.
25
Singular Genomics achieved 100% gene recovery in 1,000-plex MERFISH panels in 2023 studies.
26
BGI's stereo-seq technology mapped 1.2 million cells per cm² in spatial omics in 2023.
27
Element Biosciences' Clarity Cloud processed 10 Tb data daily with 99.99% uptime in 2023.
28
Oxford Nanopore's PromethION 2 achieved 290 Gb per flow cell with adaptive sampling in 2023.
Interpretation
Technological Advancements Interpretation
Technological advancements in genomics are accelerating fast, with platforms pushing performance benchmarks such as Illumina taking 82% of targeted NGS share in 2023 and long-read and next-gen capabilities reaching 99.5% accuracy with Oxford Nanopore, 95% CRISPR editing efficiency, and 8 million single cells per run with 10x Genomics.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Genomics Industry Statistics. Gitnux. https://gitnux.org/genomics-industry-statistics
MLA
Lars Eriksen. "Genomics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/genomics-industry-statistics.
Chicago
Lars Eriksen. 2026. "Genomics Industry Statistics." Gitnux. https://gitnux.org/genomics-industry-statistics.
Sources & references
90 datasets cited across this report · attribution is report-level